RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
2.240
-0.070 (-3.03%)
At close: Apr 23, 2025, 4:00 PM
2.200
-0.040 (-1.79%)
Pre-market: Apr 24, 2025, 4:38 AM EDT

Company Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.

The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults.

Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.

The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RedHill Biopharma Ltd.
RedHill Biopharma logo
Country Israel
Founded 2009
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 35
CEO Dror Ben-Asher

Contact Details

Address:
21 Ha’arba’a Street
Tel Aviv, 6473921
Israel
Phone 972 3 541 3131
Website redhillbio.com

Stock Details

Ticker Symbol RDHL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001553846
CUSIP Number 757468103
ISIN Number US7574682024
SIC Code 2834

Key Executives

Name Position
Dror Ben-Asher Co-Founder, Chairman and Chief Executive Officer
Razi Ingber Chief Financial Officer
Adi Frish Chief Corporate and Business Development Officer
Rick D. Scruggs Chief Commercial Officer and Director
Gilead Raday MPhil, MSc Chief Operating Officer
Alexandra Okmian Senior Business Development and Investor Relations Manager
Dr. Reza Fathi Ph.D. Senior Vice President of Research and Development
Guy Goldberg J.D. Chief Business Officer
Patricia Anderson B.Sc. RAC Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Apr 17, 2025 6-K Report of foreign issuer
Apr 16, 2025 6-K Report of foreign issuer
Apr 10, 2025 6-K Report of foreign issuer
Apr 10, 2025 20-F Annual and transition report of foreign private issuers
Apr 8, 2025 6-K Report of foreign issuer
Apr 1, 2025 6-K Report of foreign issuer
Mar 26, 2025 6-K Report of foreign issuer
Mar 25, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 18, 2025 6-K Report of foreign issuer
Mar 12, 2025 6-K Report of foreign issuer